ACC017 vs Bictegravir/lenacapavir (Bixlenvo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

ACC017

Developed by Jiangsu Aidea Pharmaceutical Group

Phase 3 in HIVsmall molecule
Partial signal

NCT06719310 · Phase 1/2 · completed

The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.

Next expected readout: June 2027 · NCT07711210 (registry estimate)

Reported efficacy

Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE (Day 1- Day 11); HIV-1 RNA viral load change from baseline (Day 11); Proportion of patients with HIV-1 RNA viral load <50 copies/mL (Day 29); Pharmacokinetics parameter: Cτ,ss (Day 10, Day 29); Pharmacokinetics parameter: Cmin,ss (Day 10); Pharmacokinetics parameter: Cmax,ss (Day 10); Pharmacokinetics parameter: AUC0-τ,ss (Day 1- Day 10); Pharmacokinetics parameter: Tmax,ss (Day 1-Day 10); Pharmacokinetics parameter: MRT0-τ,ss (Day 1-Day 10): The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. (not_applicable)

Result source: NCT06719310

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACC017Bictegravir/​lenacapavir (Bixlenvo)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT07711223—Trial running · NCT06532656
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT07711223—Trial running · NCT06532656
CD4 count, change (week 48)—Trial running · NCT07711223—Trial running · NCT06532656

HIV-1 RNA below 50 copies/mL (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656

HIV-1 RNA 50 copies/mL or more (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656

CD4 count, change (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ACC017
The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. NCT06719310 · Phase 1/2 · design grade: moderate · reviewed ClinicalTrials.gov result
Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Bictegravir/lenacapavir (Bixlenvo)'s landscape